The HSE asked the National Centre for Pharmacoeconomics (NCPE) to carry out an assessment of the applicant’s (Boehringer Ingelheim Ltd) economic dossier on the cost-effectiveness of nintedanib (Ofev®). The NCPE uses a decision framework to systematically assess whether a technology is costeffective. This includes clinical effectiveness and health related quality of life benefits, which the new ...

Author Affiliations: 1. Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA; 2. Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA; 3. Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Penn...

The HSE asked the National Centre for Pharmacoeconomics (NCPE) to carry out an assessment of the applicant’s (Novartis Ireland Ltd) economic dossier on the cost effectiveness of secukinumab (Cosentyx®). The NCPE uses a decision framework to systematically assess whether a technology is cost-effective. This includes clinical effectiveness and health related quality of life benefits, which the ne...

COPD exerts a substantial burden on health and health care systems globally and will continue to do so for the foreseeable future. Treatment however can be costly and health care providers are interested in both whether treatments can offer improvements in disease burden and whether they represent value for money. Economic evaluations seek to resolve this issue by producing results that can be ...

The National Institute for Health and Clinical Excellence (NICE) is required to Abstract consider cost effectiveness when issuing guidance about the use of health technologies within the UK NHS. Cost effectiveness is a means of supporting a system objective of maximizing population health gain from the available budget. There is a range of sources of variation between individuals in disease pro...

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 269 1. Valuation Methods for Informal Care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 271 1.1 Proxy Good Method . . . . . . . . . . . . . . . . . . . . . . . . . . ...